Lbp Am Sa Sells 15,400 Shares of Bristol Myers Squibb Company (NYSE:BMY)

LBP AM SA lessened its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 3.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 423,719 shares of the biopharmaceutical company's stock after selling 15,400 shares during the period. LBP AM SA's holdings in Bristol Myers Squibb were worth $25,843,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Pinney & Scofield Inc. acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $25,000. Park Square Financial Group LLC acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $26,000. Fairway Wealth LLC acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $28,000. Transce3nd LLC acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $28,000. Finally, Global Wealth Strategies & Associates increased its holdings in shares of Bristol Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 275 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of recent research reports. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $55.00 price objective on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. Wall Street Zen cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. UBS Group reduced their price objective on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research note on Friday, April 11th. Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective on the stock. Finally, William Blair reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $57.69.

Insider Transactions at Bristol Myers Squibb

In other news, EVP Samit Hirawat acquired 4,250 shares of the stock in a transaction dated Friday, April 25th. The shares were bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president directly owned 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.09% of the company's stock.

Bristol Myers Squibb Stock Down 3.3%

BMY traded down $1.61 during trading on Friday, hitting $46.91. The company had a trading volume of 13,670,701 shares, compared to its average volume of 12,845,758. The company has a market capitalization of $95.47 billion, a PE ratio of 17.57, a PEG ratio of 2.43 and a beta of 0.36. Bristol Myers Squibb Company has a one year low of $39.93 and a one year high of $63.33. The firm's 50-day moving average price is $47.51 and its 200 day moving average price is $53.28. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The firm's revenue was down 5.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($4.40) EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be paid a $0.62 dividend. The ex-dividend date of this dividend is Thursday, July 3rd. This represents a $2.48 annualized dividend and a yield of 5.29%. Bristol Myers Squibb's payout ratio is currently 92.88%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.